Wuxi, China, February 22, 2018 — MilliporeSigma, a leading science and technology company, today announced an additional investment to accelerate Mobius® single-use manufacturing in Wuxi, China. This investment follows a year after MilliporeSigma announced its €80m Life Science investment in Nantong, China in November 2016.
“As a leading Life Science solutions provider, we are committed to playing an active role in China’s transformation into an innovation-driven economy,” said Andrew Bulpin, head of Process Solutions, Life Science at MilliporeSigma. “This investment allows us to accelerate the development and manufacturing of biosimilars for our customers. It also demonstrates our resolve to fulfil and upgrade the life science value chain in China.”
China is fast becoming a biotech powerhouse with a promising biosimilar industry. Single-use capability is critical for biosimilar development and manufacturing because of their flexibility and efficiency.
The investment demonstrates MilliporeSigma’s commitment to support the industry’s fast growth by providing a wide range of leading, innovative solutions for customers and partners in China. Located in Wuxi China, the site expansion to add Mobius® manufacturing is expected to be completed in the second half of 2018.
MilliporeSigma recently announced additional investments of about €40m to build a robust supply chain with two new Life Science manufacturing and distribution sites in South Korea and India, and the single-use manufacturing facility in China.